Short answer:
The 135 % increase in Niagen® ingredient sales that Niagen Bioscience reported for Q2 2025 versus the same quarter a year earlier cannot be directly compared with “prior‑quarter” (i.e., Q1 2025) growth rates because the press release does not disclose the Q1‑2025 figures for Niagen® ingredient sales.
Below is a more detailed explanation of what we can (and cannot) infer from the information that was provided.
1. What the press release tells us
| Metric (Q2 2025) | Figure | YoY (vs. Q2 2024) |
|---|---|---|
| Total net sales | $31.1 M | +37 % |
| Tru Niagen® sales | $22.7 M | +22 % |
| Niagen® ingredient sales | $7.4 M | +135 % |
| Gross margin | 65.0 % | +480 bps (vs. Q2 2024) |
| Sales & marketing expense | (the excerpt cuts off) | — |
Key points:
- The 135 % increase refers specifically to the year‑over‑year (YoY) change in Niagen® ingredient sales, i.e., the sales in Q2 2025 compared with Q2 2024.
- The press release does not disclose the Q1 2025 Niagen® ingredient sales figure, nor the quarter‑over‑quarter (QoQ) percentage change from Q1 2025 to Q2 2025.
2. What “prior‑quarter growth rates” would mean
- Quarter‑over‑quarter (QoQ) growth compares one quarter’s results with the previous quarter (e.g., Q2 2025 versus Q1 2025).
- Year‑over‑year (YoY) growth (the figure we have) compares the same quarter of two consecutive years (e.g., Q2 2025 vs. Q2 2024).
Because the release only gives YoY data, we cannot calculate the QoQ growth for Niagen® ingredient sales without the missing Q1 2025 numbers.
3. Why we can’t directly compare the 135 % YoY increase to a prior‑quarter rate
- Different time frames – 135 % is a year‑over‑year increase, not a quarter‑over‑quarter increase.
- Missing data – The press release does not provide:
- Q1 2025 Niagen® ingredient sales amount.
- Q1 2025 Niagen® ingredient growth percentage (or any comparable metric).
- Potential differences in seasonality – Niagen® ingredient sales could be seasonal (e.g., higher in Q2 due to product launches, marketing cycles, etc.). Without Q1 data, we can’t assess whether the 135 % YoY jump is consistent, accelerating, or decelerating relative to the most recent quarter.
4. Reasonable inference (with caveats)
- If Q1 2025 sales were **roughly the same or lower than Q1 2024** (a plausible scenario given that the company is still scaling the ingredient business), the 135 % YoY growth could be larger than any QoQ increase.
- If Q1 2025 had already shown strong growth (e.g., 80 % YoY for Q1), the 135 % YoY figure in Q2 would indicate an accelerated growth from Q1 to Q2, suggesting the ingredient business is accelerating.
However, these are speculative and not supported by the data we have.
5. Bottom‑line answer
The 135 % increase in Niagen® ingredient sales reported for Q2 2025 is a year‑over‑year figure, and the press release does not give the prior‑quarter (Q1 2025) Niagen® ingredient sales or growth rate. Consequently, we cannot directly compare the 135 % YoY increase to a quarter‑over‑quarter growth rate, because the necessary prior‑quarter data is not provided.
If you need a precise QoQ comparison, you would need the Q1 2025 Niagen® ingredient sales figures (or the QoQ % change) that the company has not disclosed in this release. You could request this information from Niagen’s investor relations team or review their detailed quarterly filing (Form 10‑Q) for the period, which will contain the exact Q1 numbers and any QoQ growth calculations.